Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening

Journal of Medicinal Chemistry

Volumn 55, Issue 9, 2012, Pages 4142-4158

  Lavecchia, Antonio ^a   Di Giovanni, Carmen ^a   Pesapane, Ada ^a   Montuori, Nunzia ^a   Ragno, Pia ^b   Martucci, Nicola Massimiliano ^a,c   Masullo, Mariorosario ^a,c   De Vendittis, Emmanuele ^a   Novellino, Ettore ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

[3 (4,5,6 TRIHYDROXY 3 OXO 3H XANTHEN 9 YL)PROPANOIC ACID]; [4 (2 CARBOXYBENZOYL)PHTHALIC ACID]; [5 [(2 HYDROXY 4 METHYLQUINOLIN 6 YL)METHYL] 2 METHOXYBENZENESULFONIC ACID]; [5,5' [3 (PYRIDIN 2 YL) 1,2,4 TRIAZINE 5,6 DIYL]DIFURAN 2 SULFONIC ACID]; CDC25B PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING;

ANTINEOPLASTIC AGENTS; CDC25 PHOSPHATASES; CELL CYCLE; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84861040335     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201624h     Document Type: Article

References (85)

1. Nilsson, I.; Hoffman, I. Cell cycle regulation by the Cdc25 phosphatase family Prog. Cell Cycle Res. 2000, 4, 107-144
2. Jinno, S.; Suto, K.; Nagata, A.; Igarashi, M.; Kanaoka, Y.; Nojima, H.; Okayama, H. Cdc25A is a novel phosphatase functioning early in the cell cycle EMBO J. 1994, 13, 549-556
3. 2/M progression Biochem. Biophys. Res. Commun. 1999, 260, 510-515 (Pubitemid 29352093)
4. Donazelli, M.; Draetta, G. F. Regulating mammalian checkpoints through Cdc25 inactivation EMBO J. 2003, 4, 671-677 (Pubitemid 36974751)
5. Molinari, M.; Mercurio, C.; Dominguez, J.; Goubin, F.; Draetta, G. F. Human Cdc25A inactivation in response to S phase inhibition and its role in preventing premature mitosis EMBO Rep. 2000, 1, 71-79
6. Mailand, N.; Falck, J.; Lukas, C.; Syljuasen, R. G.; Welcker, M.; Bartek, J.; Lukas, J. Rapid destruction of human Cdc25A in response to DNA damage Science 2000, 288, 1425-1429 (Pubitemid 30366329)
7. Santamaria, D.; Barriere, C.; Cerqueira, A.; Hunt, S.; Tardy, C.; Newton, K.; Caceres, J. F.; Dubus, P.; Malumbres, M.; Barbacid, M. Cdk1 is sufficient to drive the mammalian cell cycle Nature 2007, 448, 811-816
8. Boutros, R.; Dozier, C.; Ducommun, B. The when and wheres of Cdc25 phosphatases Curr. Opin. Cell Biol. 2006, 18, 185-191 (Pubitemid 43375887)
9. Boutros, R.; Lobjois, V.; Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? Nature Rev. Cancer 2007, 7, 495-507 (Pubitemid 46985396)
10. Lavecchia, A.; Di Giovanni, C.; Novellino, E. Cdc25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy Curr. Med. Chem. 2009, 16, 1831-1849
11. Rudolph, J. Cdc25 phosphatases: structure, specificity, and mechanism Biochemistry 2007, 46, 3595-3604 (Pubitemid 46493460)
12. Galaktionov, K.; Lee, A. K.; Eckstein, J.; Draetta, G.; Meckler, J.; Loda, M.; Beach, D. Cdc25 phosphatases as potential human oncogenes Science 1995, 269, 1575-1577
13. Hernàndez, S.; Bessa, X.; Beà, S.; Hernàndez, L.; Nadal, A.; Mallofré, C.; Muntane, J.; Castells, A.; Fernàndez, P. L.; Cardesa, A.; Campo, E. Differential expression of Cdc25 cell-cycle- activating phosphatases in human colorectal carcinoma Lab. Invest. 2001, 81, 465-473 (Pubitemid 32298791)
14. Takemara, I.; Yamamoto, H.; Sekimoto, M.; Ohue, M.; Noura, S.; Miyake, Y.; Matsumoto, T.; Aihara, T.; Tomita, N.; Tamaki, Y.; Sakita, I.; Kikkawa, N.; Matsuura, N.; Shiozaki, H.; Monden, M. Overexpression of Cdc25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma Cancer Res. 2000, 60, 3043-3050 (Pubitemid 30395833)
15. Hernàndez, S.; Hernandez, L.; Bea, S.; Pinyol, M.; Nayach, I.; Bellosillo, B.; Nadal, A.; Ferrer, A.; Fernandez, P. L.; Montserrat, E.; Cardesa, A.; Cardes, E.; Campo, E. Cdc25A and the splicing variant Cdc25B2, but not Cdc25B1, -B3 or -C, are overexpressed in aggressive human non-Hodgkin's lymphomas Int. J. Cancer 2000, 89, 148-152 (Pubitemid 30185923)
16. Ngan, E. S. W.; Hashimoto, Y.; Ma, Z.-Q.; Tsai, M. J.; Tsai, S. Y. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer Oncogene 2003, 22, 734-739 (Pubitemid 36269286)
17. Guo, J.; Kleeff, J.; Li, J.; Ding, J.; Hammer, J.; Zhao, Y.; Giese, T.; Korc, M.; Büchler, M. W.; Friess, H. Expression and functional significance of Cdc25B in human pancreatic ductal adenocarcinoma Oncogene 2004, 23, 71-81 (Pubitemid 38142241)
18. Wu, W. G.; Fan, Y. H.; Kemp, B. L.; Walsh, G.; Mao, L. Overexpression of Cdc25A and Cdc25B is frequent in primary nonsmall cell lung cancer but is not associated with overexpression of c-myc Cancer Res. 1998, 58, 4082-4085 (Pubitemid 28440560)
19. Sasaki, H.; Yukiue, H.; Kobayashi, Y.; Tanahashi, M.; Moriyama, S.; Nakashima, Y.; Fukai, I.; Kiriyama, M.; Yamakawa, Y.; Fujii, Y. Expression of the Cdc25B gene as a prognosis marker in non-small cell lung cancer Cancer Lett. 2001, 173, 187-192 (Pubitemid 32971937)
20. Fernandez-Vidal, A.; Ysebaert, L.; Didier, C.; Betous, R.; Toni, F. D.; Prade-Houdellier, N.; Demur, C.; Contour-Galcera, M.-O.; Prevost, G. P.; Ducommun, B.; Payrastre, B.; Racaud-Sultan, C.; Manenti, S. Cell adhesion regulates Cdc25A expression and proliferation in acute myeloid leukemia Cancer Res. 2006, 66, 7128-7135 (Pubitemid 44197690)
21. Fauman, E. B.; Cogswell, J. P.; Lovejoy, B.; Rocque, W. J.; Holmes, W.; Montana, V. G.; Piwnica-Worms, H.; Rink, M. J.; Saper, M. A. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A Cell 1998, 93, 617-625 (Pubitemid 28240722)
22. Reynolds, R. A.; Yem, A. W.; Wolfe, C. L.; Deibel, M. R.; Chidester, C. G.; Watenpaugh, K. D. Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle J. Mol. Biol. 1999, 293, 559-568 (Pubitemid 29512056)
23. Rudolph, J. Targeting the Neighbor's Pool Mol. Pharmacol. 2004, 66, 780-2 (Pubitemid 39319448)
24. Lavecchia, A.; Coluccia, A.; Di Giovanni, C.; Novellino, E. Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective Anticancer Agents Med. Chem. 2008, 8, 843-856
25. Lavecchia, A.; Di Giovanni, C.; Novellino, E. Inhibitors of Cdc25 Phosphatases as Anticancer Agents - A Patent Review Expert Opin. Ther. Pat. 2010, 20, 405-425
26. Nishikawa, Y.; Carr, B. I.; Wang, M.; Kar, S.; Finn, F.; Dowd, P.; Zheng, Z. B.; Kerns, J.; Naganathan, S. Growth inhibition of hepatoma cells induced by Vitamin K and its analogs J. Biol. Chem. 1995, 270, 28304-28310
27. Tamura, K.; Southwick, E. C.; Kerns, J.; Rosi, K.; Carr, B. I.; Wilcox, C.; Lazo, J. S. Cancer Res. 2000, 60, 1317-1325
28. Lazo, J. S.; Nemoto, K.; Pestell, K. E.; Cooley, K.; Southwick, E. C.; Mitchell, D. A.; Furey, W.; Gussio, R.; Zaharevitz, D. W.; Joo, B.; Wipf, P. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors Mol. Pharmacol. 2002, 61, 720-728 (Pubitemid 34273150)
29. Cao, S.; Forster, C.; Brisson, M.; Lazo, J. S.; Kingston, D. G. I. Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp Bioorg. Med. Chem. 2005, 13, 999-1003 (Pubitemid 40164583)
30. Brezak, M. C.; Quaranta, M.; Contour-Galcera, M. O.; Lavergne, O.; Mondesert, O.; Auvray, P.; Kasprzyk, P. G.; Prevost, G.; Ducommun, B. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases Mol. Cancer Ther. 2005, 4, 1378-1387
31. Cazales, M.; Boutros, R.; Brezak, M. C.; Chaumeron, S.; Prévost, G.; Ducommun, B. Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly Mol. Cancer Ther. 2007, 6, 318-325 (Pubitemid 46206696)
32. Brezak, M. C.; Valette, A.; Quaranta, M.; Galcera-Contour, M. O.; Jullien, D.; Lavergne, O.; Frongia, C.; Bigg, D.; Kasprzyk, P. G.; Prevost, G.; Ducommun, B. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells Int. J. Cancer 2009, 124, 1449-1456
33. Lavecchia, A.; Cosconati, S.; Limongelli, V.; Novellino, E. Modeling of Cdc25B dual specificity protein phosphatase inhibitors: docking of ligands and enzymatic inhibition mechanism ChemMedChem 2006, 1, 540-550 (Pubitemid 43759765)
34. Park, H.; Bahn, Y. J.; Jung, S.-K.; Jeong, D. G.; Lee, S.-H.; Seo, I.; Yoon, T.-S.; Kim, S. J.; Ryu, S. E. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening J. Med. Chem. 2008, 51, 5533
35. Thor, H.; Smith, M. T.; Hartzell, P.; Bellomo, G.; Jewell, S. A.; Orrenius, S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells J. Biol. Chem. 1982, 257, 12419-12425 (Pubitemid 13180138)
36. Morrison, H.; Jernstrom, B.; Nordenskjold, M.; Thor, H.; Orrenius, S. Induction of DNA damage by menadione (2-methyl-1,4-naphthoquinone) in primary cultures of rat hepatocytes Biochem. Pharmacol. 1984, 33, 1763-1769 (Pubitemid 14109443)
37. Han, Y.; Shen, H.; Carr, B. I.; Wipf, P.; Lazo, J. S.; Pan, S. S. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors J. Pharmacol. Exp. Ther. 2004, 309, 64-70 (Pubitemid 38393115)
38. Irwin, J. J.; Shoichet, B. K. ZINC - a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-182 (Pubitemid 40736970)
39. GLIDE, version 5.7; Schrodinger, LLC: New York, 2011; http://www.schrodinger.com
40. Jorgensen, W. L. QikProp, version 3.4; Schrodinger, LLC: New York, 2011.
41. MDL CrossFire Commander, release version 7.0 SP2; Elsevier MDL: San Ramon, CA; www.mdli.com.
42. PubChem Compound database available at http://www.ncbi.nlm.nih.gov/sites/ entrez/.
43. Sohn, J.; Kiburz, B.; Li, Z.; Deng, L.; Safi, A.; Pirrung, M. C.; Rudolph, J. Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones J. Med. Chem. 2003, 46, 2580-2588 (Pubitemid 36702527)
44. Brisson, M.; Nguyen, T.; Wipf, P.; Joo, B.; Day, B. W.; Skoko, J. S.; Schreiber, E. M.; Foster, C.; Bansal, P.; Lazo, J. S. Redox regulation of Cdc25B by cell-active quinolinediones Mol. Pharmacol. 2005, 68, 1810-1820 (Pubitemid 41656028)
45. Brisson, M.; Foster, C.; Wipf, P.; Joo, B.; Tomko, R. J., Jr.; Nguyen, T.; Lazo, J. S. Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone Mol. Pharmacol. 2007, 71, 184-192 (Pubitemid 46020988)
46. Zhou, Y. B.; Feng, X.; Wang, L. N.; Du, J. Q.; Zhou, Y. Y.; Yu, H. P.; Zang, Y.; Li, J. Y.; Li, J. LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation. Zhou et al Acta Pharmacol. Sin. 2009, 30, 1359-1368
47. Hilal, S. H.; Karickhoff, S. W.; Carreira, L. A. Estimation of microscopic, zwitterionic ionization constants, isoelectric point and molecular speciation of organic compounds Talanta 1999, 50, 827-840
48. Müller, P. A new photoremovable protecting group absorbing above 500 nm: (6-hydroxy-3-ox-3 H -xanthen-9-yl)methyl and its derivatives. Ph.D. dissertation, University of Basel, December 2007.
49. McCain, D. F.; Wu, L.; Nickel, P.; Kassack, M. U.; Kreimeyer, A.; Gagliardi, A.; Collins, D. C.; Zhang, Z. Y. Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases J. Biol. Chem. 2004, 279, 14713-14725 (Pubitemid 38618861)
50. Park, H.; Bahn, Y. J.; Jung, S.-K.; Jeong, D. G.; Lee, S.-H.; Seo, I.; Yoon, T.-S.; Kim, S. J.; Ryu, S. E. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening J. Med. Chem. 2008, 51, 5533-5541
51. Johnston, P. A.; Foster, C. A.; Tierno, M. B.; Shun, T. Y.; Shinde, S. N.; Paquette, W. D.; Brummond, K. M.; Wipf, P.; Lazo, J. S. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library Assay Drug Dev. Technol. 2009, 7, 250-265
52. Sun, Y. W.; Huang, W. J.; Hsiao, C. J.; Chen, Y. C.; Lu, P. H.; Guh, J. H. Methoxychalcone induces cell-cycle arrest and apoptosis in human hormone-resistant prostate cancer cells through PI 3-kinase-independent inhibition of mTOR pathways Prostate 2010, 70, 1295-1306
53. Prasad, S.; Kaur, J.; Roy, P.; Kalra, N.; Shukla, Y. Theaflavins induce G2/M arrest by modulating expression of p21waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells Life Sci. 2007, 81, 1323-1331 (Pubitemid 47599530)
54. Chen, R. Q.; Yang, Q. K.; Lu, B. W.; Yi, W.; Cantin, G.; Chen, Y. L.; Fearns, C.; Yates, J. R., III; Lee, J. D. CDC25B mediates rapamycin-induced oncogenic responses in cancer cells Cancer Res. 2009, 69, 2663-2668
55. Wei, F.; Xie, Y.; Tao, L.; Tang, D. Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation Cell. Signalling 2010, 22, 1783-1789
56. Brault, L.; Bagrel, D. Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells Life Sci. 2008, 82, 315-323
57. Takagaki, K.; Katsuma, S.; Kaminishi, Y.; Horio, T.; Tanaka, T.; Ohgi, T.; Yano, J. Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells Genes Cells 2005, 10, 97-106 (Pubitemid 40287513)
58. Brisson, M.; Nguyen, T.; Vogt, A.; Yalowich, J.; Giorgianni, A.; Tobi, D.; Bahar, I.; Stephenson, C. R.; Wipf, P.; Lazo, J. S. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase Mol. Pharmacol. 2004, 66, 824-833 (Pubitemid 39319454)
59. Li, C.; Xu, L.; Wolan, D. W.; Wilson, I. A.; Olson, A. J. Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors J. Med. Chem. 2004, 47, 6681-6690 (Pubitemid 40053757)
60. Contour-Galcera, M. O.; Sidhu, A.; Prévost, G.; Bigg, D.; Ducommun, B. What's new on CDC25 phosphatase inhibitors Pharmacol. Ther. 2006, 115, 1-12
61. Jiang, Z. X.; Zhang, Z. Y. Targeting PTPs with small molecule inhibitors in cancer treatment Cancer Metastasis Rev. 2008, 27, 263-272
62. Keinan, S.; Paquette, W. D.; Skoko, J. J.; Beratan, D. N.; Yang, W.; Shinde, S.; Johnston, P. A.; Lazo, J. S.; Wipf, P. Computational design, synthesis and biological evaluation of para-quinone based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B Org. Biomol. Chem. 2008, 6, 3256-3263
63. QikProp, version 3.4; Schrödinger LLC: New York, 2011.
64. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 1991, 175, 880-885
65. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 (Pubitemid 30047768)
66. Buhrman, G.; Parker, B.; Sohn, J.; Rudolph, J.; Mattos, C. Structural mechanism of oxidative regulation of the phosphatase Cdc25B via an intramolecular disulfide bond Biochemistry 2005, 44, 5307-5316 (Pubitemid 40489970)
67. Taylor, N. R.; Borhani, D.; Epstein, D.; Rudolph, J.; Ritter, K.; Fujimori, T.; Robinson, S.; Eckstein, J.; Haupt, A.; Walker, N.; Dixon, R.; Choquette, D.; Blanchard, J.; Kluge, A.; Pal, K.; Bockovich, N.; Come, J.; Hediger, M. Crystal structure of CDC25 proteins and its use in rational design of inhibitors. Patent WO 2001/16300 A2, 2001.
68. Maestro, version 9.2; Schrödinger LLC: New York, 2011.
69. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236 (Pubitemid 26399746)
70. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26 (Pubitemid 33653411)
71. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. GLIDE: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749 (Pubitemid 38380917)
72. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196 (Pubitemid 44595196)
73. Jaguar, version 7.8; Schrödinger, LLC: New York, 2011.
74. Zhao, Y.; Truhlar, D. G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals Theor. Chem. Acc. 2008, 120, 215-241
75. a values and tautomers of isoguanine and xanthine Chem. Res. Toxicol. 2003, 16, 1455-1462 (Pubitemid 37464467)
76. a values of guanine in water: density functional theory calculations combined with Poisson-Boltzmann continuum-solvation model J. Phys. Chem. B 2003, 107, 344-357
77. Hwang, S.; Jang, Y. H.; Chung, D. S. Gas phase proton affinity, basicity, and pK(a) values for nitrogen containing heterocyclic aromatic compounds Bull. Korean Chem. Soc. 2005, 26, 585-588 (Pubitemid 40688083)
78. Tannor, D. J.; Marten, B.; Murphy, R.; Friesner, R. A.; Sitkoff, D.; Nicholls, A.; Ringnalda, M.; Goddard, W. A., III; Honig, B. Accurate first principles calculation of molecular charge distributions and solvation energies from ab initio quantum mechanics and continuum dielectric theory J. Am. Chem. Soc. 1994, 116, 11875-11882
79. Marten, B.; Kim, K.; Cortis, C.; Friesner, A.; Murphy, R. B.; Ringnalda, M. N.; Sitkoff, D.; Honig, B. New model for calculation of solvation free energies: correction of self-consistent reaction field continuum dielectric theory for short-range hydrogen-bonding effects J. Phys. Chem. 1996, 100, 11775-11788 (Pubitemid 126788600)
80. Ihlenfeldt, W. D.; Voigt, J. H.; Bienfait, B.; Oellien, F.; Nicklaus, M. C. Enhanced CACTVS browser of the Open NCI Database J. Chem. Inf. Comput. Sci. 2002, 42, 46-57 (Pubitemid 35355324)
81. Willett, P. Similarity-based approaches to virtual screening Biochem. Soc. Trans. 2003, 31, 603-606 (Pubitemid 36750739)
82. Martin, Y. C.; Kofron, J. L.; Traphagen, L. M. Do structurally similar molecules have similar biological activity? J. Med. Chem. 2002, 45, 4350-4358 (Pubitemid 35025581)
83. Bhattacharjee, H.; Sheng, J.; Ajees, A. A.; Mukhopadhyay, R.; Rosen, B. P. Adventitious arsenate reductase activity of the catalytic domain of the human Cdc25B and Cdc25C phosphatases Biochemistry 2010, 49, 802-809
84. Cory, A. H.; Owen, T. C.; Barltrop, J. A.; Cory, J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture Cancer Commun. 1991, 3, 207-212
85. Chiaviello, A.; Paciello, I.; Postiglione, I.; Crescenzi, E.; Palumbo, G. Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis Cell Proliferation 2010, 43, 480-493